Cure My Disease

Don't miss your cure!

 Log in / Sign up

New clotting factor combo aims to tame von willebrand bleeding

NCT ID NCT04106908

Disease control Sponsor: Octapharma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study looks at how well Eqwilate, a concentrated mix of two clotting proteins (VWF and FVIII), controls bleeding in people with von Willebrand disease. It includes patients aged 6 and older who use Eqwilate on demand, before surgery, or as regular prevention. Researchers track bleeding control, factor levels, and any side effects in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Eqwilate, a concentrate of von Willebrand factor and factor VIII
What this could lead to
If successful, this could confirm Eqwilate as a reliable option for managing bleeding episodes and preventing bleeds during surgery in people with von Willebrand disease.
What could go wrong
This is a small, observational study with no comparison group, so results may not apply to all patients. There is also a risk of developing inhibitors that reduce treatment effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

38 people

The number who actually took part.

Started

Nov 2019

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will involve patients (≥ 6 years of age) from the participating centres treated with Eqwilate® (either on-demand, as perioperative prophylaxis, or as prophylaxis) during the time inclusion period will be opened.

Ages

6 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The study will involve patients (≥ 6 years of age) from the participating centres treated with Eqwilate® (either on-demand, as perioperative prophylaxis, or as prophylaxis) during the time inclusion period will be opened. Patients will be of any VWD type, previously treated or untreated. Exclusion Criteria: * N/A

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VWD - von Willebrand's disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

von Willebrand disease (hereditary or acquired)

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VWD - von Willebrand's disease

Contacts and locations

Locations

  • Caen Study Site

    Caen, 14033, France

  • Clamart Study Site

    Clamart, 92141, France

  • Paris Study Site - Lariboisiere

    Paris, 75010, France

  • Paris Study Site - Necker

    Paris, 75015, France

  • Rennes Study Site

    Rennes, 35033, France

  • Rouen Study Site

    Rouen, 76031, France

  • Saint Denis Study Site

    Saint-Denis, 97405, France

  • Saint Denis Study Site - Pediatrie

    Saint-Denis, 97405, France

  • Saint-Etienne Study Site

    Saint-Etienne, 42055, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.